Publications
Export 36 results:
Filters: Author is Marie-France Demers [Clear All Filters]
“Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.”, J Psychopharmacol, vol. 37, no. 4, pp. 370-377, 2023.
“Gaming Disorder and Psychotic Disorders: A Scoping Review.”, Psychopathology, vol. 56, no. 4, pp. 315-323, 2023.
“Problem gambling among people with first-episode psychosis: protocol for a prospective multicenter cohort study.”, BMC Psychiatry, vol. 23, no. 1, p. 287, 2023.
“Sex-specific immune mechanisms in PTSD symptomatology and risk: A translational overview and perspectives.”, Brain Res Bull, vol. 195, pp. 120-129, 2023.
“Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach”, Acta Psychiatrica Scandinavica, vol. 145, no. 5, pp. 469 - 480, 2022.
, “Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach.”, Acta Psychiatr Scand, vol. 145, no. 5, pp. 469-480, 2022.
“Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study.”, Br J Psychiatry, pp. 1-8, 2022.
“Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.”, Clin Psychopharmacol Neurosci, vol. 20, no. 1, pp. 194-198, 2022.
“Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation.”, Ther Adv Psychopharmacol, vol. 12, p. 20451253221136021, 2022.
“A Chart Audit Study of Clozapine Utilization in Early Psychosis.”, J Clin Psychopharmacol, vol. 41, no. 3, pp. 275-280, 2021.
, “Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.”, J Psychopharmacol, vol. 35, no. 9, pp. 1152-1157, 2021.
, “Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.”, CNS Drugs, vol. 35, no. 4, pp. 461-468, 2021.
, “[Psychopharmacology of First Episode Psychosis: An Approach Based on Recovery].”, Sante Ment Que, vol. 46, no. 2, pp. 113-137, 2021.
“Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.”, World J Biol Psychiatry, pp. 1-8, 2020.
, “Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports.”, J Clin Psychopharmacol, vol. 40, no. 2, pp. 191-194, 2020.
, “"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients.”, Psychopharmacology (Berl), 2020.
, “Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence.”, J Clin Psychopharmacol, vol. 39, no. 4, pp. 393-397, 2019.
, “Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use.”, Asian J Psychiatr, 2018.
, “More intensive probing increases the detection of social anxiety disorders in schizophrenia.”, Psychiatry Res, vol. 268, pp. 358-360, 2018.
, “Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity.”, J Psychiatry Neurosci, vol. 43, no. 4, pp. 287-288, 2018.
, “[Initiating an antipsychotic drug treatment for schizophrenia: the situation in Quebec, Canada, from 1998 to 2006].”, Sante Ment Que, vol. 42, no. 1, pp. 85-103, 2017.
, “One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada.”, Schizophr Res, vol. 185, pp. 96-100, 2017.
, “Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.”, Acta Psychiatr Scand, vol. 134, no. 5, pp. 374-384, 2016.
, “Comorbidity between anxiety disorders and recent-onset psychotic disorders.”, Schizophr Res, vol. 166, no. 1-3, pp. 353-4, 2015.
, “Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.”, Am J Drug Alcohol Abuse, vol. 34, no. 1, pp. 75-82, 2008.
,